// App-Quantinova.ai

BSH19‐PO‐043 : Mutational profiling in triple‐negative essential thrombocythaemia with targeted next‐generation sequencing

Researchers

Presenter

  • O. Michail

Principal Investigators

  • M. Catherwood

  • R. Cuthbert

  • C. Arnold

  • R. McAllister

  • M.F. McMullin

Medical Centers

  • Department of Haematology, Belfast Health and Social Care Trust

  • Centre for Medical Bioinformatics, Queen's University of Belfast, Belfast, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Acute myelocytic leukemia

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • MPL proto-oncogene, thrombopoietin receptor

  • Breakpoint Cluster Region

  • Calreticulin

  • Chimerin 2

  • DNA methyltransferase 3 alpha

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • Isocitrate dehydrogenase 1

  • Isocitrate dehydrogenase 2

  • Tet methylcytosine dioxygenase 2

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved